Cadrenal Therapeutics Reports $13.2 Million Net Loss and Plans for Future Funding

Cadrenal Therapeutics, Inc., a late-stage biopharmaceutical company focused on developing therapies for life-threatening immune and thrombotic conditions, reported a net loss of approximately $13.2 million for the fiscal year ended December 31, 2025, compared to a net loss of $10.7 million in the previous year. The company's total operating expenses increased by 23% to $13.5 million, driven primarily by a 39% rise in general and administrative expenses, which were attributed to costs associated with being a public company, stock-based compensation, and consulting fees. Research and development expenses slightly decreased by 2% to $4.1 million, reflecting a reduction in consulting expenses offset by increased costs related to asset purchase agreements.

In December 2025, Cadrenal completed the acquisition of a 12-lipoxygenase (12-LOX) platform of assets from Veralox Therapeutics, which included the lead product candidate CAD-1005, a selective 12-LOX inhibitor aimed at treating heparin-induced thrombocytopenia (HIT). The acquisition involved a cash payment of $200,000, contingent milestone payments up to $15 million, and royalty payments. The company also raised approximately $2.2 million through a registered direct offering and generated $4.9 million from sales of common stock via its at-the-market facility during the year.

As of December 31, 2025, Cadrenal had cash and cash equivalents of $4.0 million, down from $10.0 million the previous year. The company anticipates that its existing cash resources will not be sufficient to meet its operational needs for the next twelve months, raising substantial doubt about its ability to continue as a going concern. To address this, Cadrenal plans to seek additional capital through equity offerings, strategic partnerships, and debt financing. However, there is no assurance that such funding will be available on acceptable terms.

Cadrenal's product pipeline includes CAD-1005, tecarfarin, and frunexian, with CAD-1005 receiving orphan drug and fast track designations from the FDA. The company is preparing for a pivotal Phase 3 clinical trial for CAD-1005, which is subject to FDA review and approval. The company has not yet submitted a New Drug Application (NDA) to the FDA, and its success depends on the outcomes of ongoing and future clinical trials. The competitive landscape includes established therapies, and the company faces significant risks related to regulatory approvals, market acceptance, and potential product liability claims.

Looking ahead, Cadrenal's management remains focused on advancing its clinical programs and securing necessary funding to support its operations. The company acknowledges the challenges it faces, including the need for successful clinical trial outcomes, regulatory approvals, and effective commercialization strategies to achieve profitability in the future.